Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?Zacks Investment Research • 04/05/24
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)PRNewsWire • 04/02/24
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024PRNewsWire • 02/01/24
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH ConferencePRNewsWire • 12/11/23
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in MelanomaPRNewsWire • 12/05/23
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023PRNewsWire • 10/26/23
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023PRNewsWire • 07/27/23
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BIDPRNewsWire • 07/06/23